Biomarin Pharmaceutical Inc at Jefferies London Healthcare Conference Transcript
For those who don't know me, my name is Akash Tewari. I'm one of the therapeutic analysts here at Jefferies, and I have the pleasure of hosting BioMarin. And joining us today, we have Brian Mueller, CFO; and Jeff Ajer, Chief Commercial Officer, 2 of the people I would love to talk to, especially as BioMarin is transitioning from not only just a rare disease company, but what we're hoping for is a real EPS and revenue acceleration story, something that I think really changes the financial profile of the company and really expands the amount of shareholders who are going to be interested in your stock over the next few years.
Maybe before I get in with my own specific questions, I'll hand it off to Brian for some opening remarks, and we'll take it from there.
Thank you, Akash. I appreciate it. Really appreciate the opportunity to be with you in London here today.
Here we are just a few weeks from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
